Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 0.29.

  • Exagen's Equity Ratio fell 216.46% to 0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29, marking a year-over-year decrease of 216.46%. This contributed to the annual value of 0.21 for FY2024, which is 4643.46% down from last year.
  • Exagen's Equity Ratio amounted to 0.29 in Q3 2025, which was down 216.46% from 0.36 recorded in Q2 2025.
  • Exagen's 5-year Equity Ratio high stood at 0.74 for Q1 2021, and its period low was 0.16 during Q1 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.45 (2023), whereas its average is 0.47.
  • Per our database at Business Quant, Exagen's Equity Ratio soared by 2888.86% in 2021 and then plummeted by 5961.31% in 2025.
  • Over the past 5 years, Exagen's Equity Ratio (Quarter) stood at 0.69 in 2021, then dropped by 28.43% to 0.49 in 2022, then fell by 19.07% to 0.4 in 2023, then crashed by 46.43% to 0.21 in 2024, then skyrocketed by 35.25% to 0.29 in 2025.
  • Its Equity Ratio stands at 0.29 for Q3 2025, versus 0.36 for Q2 2025 and 0.16 for Q1 2025.